BIKE^TM: the Next Generation in Vector Design

Adeno-associated viruses (AAVs) are non-pathogenic viruses that can be engineered to deliver DNA to drive the endogenous production of therapeutic proteins within specific target tissues. By programming cells to produce particular proteins, AAV gene therapies can convert cells into local “biofactories” for these therapeutic proteins to achieve their desired clinical effect.

At Iragen Therapeutics, we harness the power of AAVs to address a broad range of diseases. BIKE (Biocompatible Implemented Kinetic Effusion) is our proprietary, computationally-derived answer to AAV design. By utilizing Artificial Intelligence to improve tissue specificity and to enhance manufacturability of our gene therapies, Iragen leads the way in hardnessing the potential of effective gene therapies across the board.

Currently, Iragen develops gene therapies for diseases with well-understood biology and established clinical endpoints, and where the durable expression of a particular therapeutic protein could have a transformative clinical impact. Our pipeline includes internally developed products as well as programs originated at leading academic institutions around the world.